Kite Pharma

Kite Pharma

Employees:
450
Market Cap:
$4.56 billion
Revenue:
$22 million
Net Income:
$-267.07 million
NASDAQ:
KITE

Kite Pharma is a publicly held, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune systems ability to recognize and eradicate tumors. The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who serves as the companys chairman, president and chief executive officer. Wikipedia

Kite Pharma

Kite Pharma is a publicly held, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune systems ability to recognize and eradicate tumors. The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who serves as the companys chairman, president and chief executive officer. Wikipedia

Employees:
450
Market Cap:
$4.56 billion
Revenue:
$22 million
Net Income:
$-267.07 million
NASDAQ:
KITE